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Case Report
Successful management of invasive aspergillosis with voriconazole and
amphoteracin B therapy in a patient with Acute Mycloid Leukemia (AML-M2)
Nauman Fazal Manzoor,1 Sidra Azim,2 Zehra Fadoo3
Medical Student,1,2 Department of Paediatrics,3 Aga Khan University Hospital, Karachi.
Abstract
An eleven year old boy presented with one month’s
history of fever and weight loss. He was diagnosed with
Acute Mycloid Leukemia (AML-M2). During treatment he
developed recurrent infections with neutropenia requiring
prolonged antibiotics and subsequently developed invasive
aspergillosis. He was treated with amphotericin B and
Voriconazole. This case shows the efficacy and safety of
combined antifungal therapy, including voriconazole, for
invasive aspergillosis complicating AML.
Introduction
Haematological malignancies are associated with
many opportunistic infections of which invasive
aspergillosis (IA) represents an important devastating
fungal infection.1 IA complicates 5-29% of the cases of
Acute Mycloid Leukemia (AML) and the risk is correlated
with the degree of Immuno-suppression which depends on
the disease itself and the subsequent chemotherapy.1-3 IA
remains a diagnostic and therapeutic challenge for any
physician. Despite advanced diagnostic modalities which
allow earlier diagnosis and aggressive intervention, the
mortality rate remains unacceptably high that is 50-70%.2,3
Previously various Anti-Fungal therapeutic agents have
been used to treat IA in patients with haematological
malignancies including Intravenous amphotericin B
deoxycholate (D AmB), Liposomal Amphotericin B (L
AmB), Itraconazole, but the outlook for the patients
remained dismal.3 Voriconazole is a triazole derivative
which has been used frequently due to its potency, broad
spectrum activity, clinical efficacy, safety and tolerance.4,5
In the past decades D AmB was the standard therapy, but it
was associated with a poor outcome. Numerous case series
and randomized control trials have shown that Voriconazole
is superior to amphotericin B in the treatment of IA and is
now considered the First line therapy in many treatment
centers.6 Here we present a case of AML-M2 complicated
with invasive aspergillosis being treated with Voriconazole.
Case Report
An eleven year old boy, known case of Atrial Septal
Defect (ASD) with Tricuspid regurgitation, diagnosed at
birth presented to us with one month history of fever and
progressive weight loss. Physical examination revealed
hepatomegaly, supraclavicular lymph nodes and pansystolic
murmur. Complete blood count (CBC) showed low counts
with peripheral blasts. Subsequent bone marrow
examination and immunophenotyping confirmed the
diagnosis of Acute Myeloid Leukaemia (AML-M2).
Cerebrospinal Fluid (CSF) was clear. 
He was started on chemotherapy based on the
Medical Research Council (MRC-10) protocol (Details in
Table). On fifth day of induction he developed febrile
neutropenia for which cultures were sent and he was started
on broad spectrum antibiotics. He was also evaluated by
Table: Details of Chemotherapy.( Medical Research Council).
Induction Ara-C(Cytarabine) 100mg/m2 IV  Day 1-8 Q12Hrly
(Course 1& 2) IV Day1, 3 & 5
ADE Daunorubicicn 50 mg/m2 IV   Day1-5
VP 16(Etoposide) 100mg/m2 Day 1 only
Triple IT (HC,Ara-C,MTX
Course 3 Idarubicin 10mg/m2 IV Day 1-2
Cytarabine 200mg/m2 IV Day 1-5
VP 16(Etoposide) 100mg/m2 IV Day1-5
Triple IT* (HC,Ara-C,MTX) Day 1 only
Consolidation Ara-C(Cytarabine) 3gm/m2 IV Day1,2,8 and 9
Course 4 Asparginase 6000mg/m2 IM IV  Day 2& 9
Clasp
* Triple IT (HC,Ara-C,MTX): (Triple Intrathecal): Methotrexate (MTX), hydrocortisone (HC), and cytarabine (ara-C)
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cardiologist and was prescribed furosemide and enalapril.
After achieving bone marrow remission he received
2nd Induction. During this admission he developed fever on
3rd day and blood cultures grew salmonella paratyphi for
which he received IV meropenem, amikacin with
amphotericin as empiric for fever/neutropenia.
Echocardiogram done at this time revealed vegetations on
right coronary sinus. A repeat blood culture grew
Enterobacter species sensitive to meropenem. Once his
counts recovered he was discharged on IV meropenem for a
total of 3 weeks.
Course three was tolerated well with no need of
prolonged admission. After 4th cycle he developed febrile
neutropenia with redness and pain at portacath site and
blood culture grew staphylococus aureus, thus portacath
was removed. He was treated with meropenem,
vancomycin, amikacin and amphotericin but fever did not
subside. Serial Chest X-rays (CXR) revealed bilateral
pneumonia with pneumatocele formation. Follow up CT
scan (Figure-1) demonstrated multiple bilateral cavities in
lungs filled with soft-tissue material. Ill-defined low
attenuating areas were also noted in segment 4 and 6 of liver
and both kidneys. Appearance was suggestive of
Aspergillosis.  After consultation with infectious disease
team he was continued on amphotericin with addition of
voriconozole. He was discharged on oral Voriconazole after
counts stabilized and fever settled.
He was admitted again in January with abdominal
pain and was diagnosed as a case of acute appendicitis, and
underwent appendicectomy. Repeat CT scan (Figure-2)
revealed complete resolution of fungal balls in the lung
cavities but not in the renal lesions. He was then advised IV
amphotericin 1mg/kg every other day together with oral
Voriconazole and discharged.
He completed his full course of ampotericin B (3
months) and Voriconazole for 6 months in June 2007.
Repeat CT showed resolution of chest and abdominal
lesions on scan. He has been off therapy and doing well for
more than a year after completion of therapy for AML-M2
with multiple life threatening events like infective
endocarditis, Staph aureus sepsis and invasive aspergillosis.
Discussion
Invasive aspergillosis (IA) is a frequently
encountered infection in AML patients undergoing
induction chemotherapy. IA in children is associated with
mortality ranging from 68% to 77% as compared to other
Invasive Fungal Infections.7 Studies directed at Paediatric
oncology patients show a protean 15-34% survival rate.1,8
Exclusion of Haematopoietic Stem Cell Transplantation
(HSCT) recipients improves the survivorship to 82% due to
prolonged immunosuppression associated with HSCT. Both
acute infection and relapse are particularly associated with
severe neutropenia, use of broad-spectrum antibiotics or
high-dose corticosteroids. Due to the fact that causative
factor may remain viable in the initial lesions, IA patients
have a higher risk of reactivation of the infection with
further chemotherapy. Patients with acute leukaemia and a
history of previously treated IA on additional chemotherapy
are at a risk of approximately 50% for recurrent invasive
aspergillosis. Due to the higher benefit risk ratio it is
universally accepted that IA is not an absolute
contraindication for further chemotherapy.9
Invasive aspergillosis remains a diagnostic challenge
especially in paediatric population due to non-specific
clinical signs. The physician should have a high degree of
clinical suspicion when dealing with febrile patients on
Figure 1 and 2: Pre and Post Treatment Ct scan show cavity of Right side filled
with soft-tissue like material, suggestive of Aspergillosis. Resolution of the disease
with combination Anti-fungal therapy.
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chemotherapy.10 However, diagnosis often remains difficult
as most of the diagnostic tools in clinical use at present
either lack specificity or acceptable sensitivity in the early
phase of the infection. Radiological imaging remains the
corner stone with the "halo" sign and "crescent sign" on CT
scan being regarded as diagnostic for invasive pulmonary
aspergillosis (IPA). In febrile neutropenic patients
systematic CT scans allow earlier diagnosis of IPA.11
Definitive diagnosis however depends on tissue biopsy,
which is precluded by the degree of cytopenia and
coagulation abnormalities in such patients. 
Antifungal therapy remains the mainstay of
treatment for invasive aspergillosis.12 But the combination
of antifungal treatment and surgical resection has shown to
dramatically improve the prognosis of IA. Aggressive
surgical resection has been associated with improved
outcome by eliminating macroscopic foci of IA that could
complicate subsequent immunosuppressive chemotherapy
but because IA is a multifocal disease at microscopic level,
there is no guarantee of complete cure with surgery. The risk
of leukaemia relapse or presence of multiple and bilateral
lesions makes the surgery impossible. Thus secondary
antifungal prophylaxis is the main option in these patients.13
Treatment of IA in the last decade resolved around
different formulations of Amphotericin B. But prolonged
use of amphoB therapy is limited by nephrotoxicity.
LipoAMB permits extended therapy due to reduced renal
toxicity.14 Itraconazole may be effective in the treatment of
microscopic IA and may prevent recurrence of clinical
infection. Despite the introduction of lipid formulations of
AmB, about 50% of patients with aspergillosis will fail
primary therapy.3
In our case, Voriconazole was used together with
Amphotericin as combination therapy in a patient with
AML and Invasive Aspergillosis not responsive to ampho B
therapy alone. Voriconazole was well tolerated in the patient
with no visual hallucinations or hepatotoxicity. This case
highlights that patients with AML complicated with
Invasive Aspergillosis (IA) may complete their
chemotherapy treatment and remain in remission with
initial aggressive intravenous therapy following ambulatory
treatment with oral voriconazole.
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